Safety evaluation of inotuzumab ozogamicin: a pharmacovigilance study based on the FAERS database
database[Title] 2025-05-13
Summary:
CONCLUSION: This study underscores the potential ADEs and associated risks with the clinical application of InO, with particular emphasis on the risks of VOD, infections, and febrile neutropenia. The implementation of a vigilant monitoring strategy is crucial for the early detection and timely management of these potential complications.